MTARC2

MTARC2 (mARC2/MOSC2) is a molybdenum cofactor-containing enzyme of the outer mitochondrial membrane that serves as the catalytic component of a three-protein N-reductive system, together with the mitochondrial cytochrome b5 isoform CYB5B and NADH cytochrome b5 reductase (PMID:22203676, PMID:23703616). EPR and isotopic-labeling of the Mo(V) state define an active site in which the molybdenum carries an exchangeable equatorial hydroxyl, an axial oxo, a protein-derived equatorial ligand, and two sulfur atoms from the molybdopterin cofactor (PMID:21916412); catalysis depends on the molybdenum center and a coordinating active-site cysteine, and on heme-loaded CYB5B as the obligate electron-transfer partner (PMID:23703616, PMID:24500710). Through this electron chain MTARC2 reduces a broad range of N-hydroxylated substrates including amidoxime prodrugs, N-hydroxylated nucleobases, N-hydroxy-sulfonamides, and N-oximes, and reduces nitrite to nitric oxide, with isoform-specific selectivity distinguishing it from mARC1 (PMID:24500710, PMID:22924387, PMID:20699408, PMID:25045021, PMID:25170804); it also reduces hydrogen peroxide, a substrate lacking a nitrogen–oxygen bond (PMID:37687214). Cellular consequences of this activity include reductive detoxification that protects cells from apoptosis induced by the mutagenic base analog N6-hydroxylaminopurine (PMID:25713076) and metabolic activation of prodrugs and mitotoxic metabolites in adipocytes (PMID:26378779). MTARC2 is the dominant N-reductive isoform in mice, where its loss reduces N-oxygenated substrate reduction and reprograms energy homeostasis, conferring resistance to high-fat-diet-induced obesity (PMID:31554661). Beyond N-reduction, MTARC2 suppresses hepatocellular carcinoma progression via Hippo-pathway- and RNF123-dependent regulation of p27 and HNF4A (PMID:32811980), and in bat cells it acts as a restriction factor against coronavirus infection through interaction with the viral Orf9b protein (PMID:42134328).

1. 2011 High

   Established where MTARC2 acts and what it does at the cellular level, resolving its localization, its essential electron-transfer partner, and a physiological function.

   Evidence Subcellular fractionation, radiolabeled benzamidoxime binding, and siRNA knockdown with enzymatic and lipid-synthesis readouts in rat liver and 3T3-L1 adipocytes

   PMID:22203676

   Open questions at the time

   • Did not resolve the catalytic mechanism at the molybdenum center
   • Functional partner CYB5B identified by knockdown but not reconstituted in vitro here
2. 2011 High

   Defined the molybdenum active-site coordination geometry, providing the structural basis for the enzyme's redox chemistry.

   Evidence Continuous-wave and pulsed EPR with 17O/D2O labeling and DFT calculations on Mo(V)-state mARC2

   PMID:21916412

   Open questions at the time

   • Identity of the protein-derived equatorial ligand not definitively assigned
   • No full crystal structure of the holoenzyme
3. 2010 Medium

   Demonstrated that MTARC2 activates prodrugs by reducing N-hydroxy-sulfonamides, extending its substrate scope to pharmacologically relevant compounds.

   Evidence Reconstituted three-component enzyme system with recombinant human and native porcine enzymes

   PMID:20699408

   Open questions at the time

   • Single substrate class
   • No cell-based confirmation
4. 2012 Medium

   Showed the system reductively detoxifies mutagenic N-hydroxylated nucleobases, linking N-reduction to protection against genotoxic base analogs.

   Evidence Reconstituted in vitro assay with recombinant three-component system and subcellular fractionation across tissues

   PMID:22924387

   Open questions at the time

   • mARC2-specific contribution not isolated in cells here
   • mARC1 reported as more efficient for these substrates
5. 2013 High

   Confirmed in human cells that CYB5B (heme-dependent), not the microsomal CYB5A, is the obligate electron-transfer partner of the mARC N-reductase.

   Evidence Reciprocal RNAi knockdown in HEK-293 and HeLa, CYB5A knockout mice, and heme-free apo-CYB5 reconstitution

   PMID:23703616

   Open questions at the time

   • Stoichiometry and assembly of the three-protein complex not resolved
6. 2014 High

   Mapped the catalytic determinants of nitrite-to-NO reduction to the molybdenum cofactor and its coordinating cysteine, identifying a non-N-O-bond physiological function.

   Evidence Reconstituted enzyme system, C273A active-site mutagenesis, tungsten-for-molybdenum substitution, and cellular expression

   PMID:24500710

   Open questions at the time

   • Cys mapping demonstrated in mARC1; equivalent in mARC2 inferred
   • Physiological relevance of NO output in vivo not established
7. 2014 Medium

   Established isoform-specific substrate selectivity, distinguishing MTARC2's reductive repertoire from mARC1's (e.g., N-oxides reduced only by mARC1).

   Evidence Reconstituted in vitro assays comparing recombinant mARC1 and mARC2 across N-oximes, hydrazones, and N-oxides

   PMID:25045021

   Open questions at the time

   • Structural basis of selectivity not defined
   • In vitro only
8. 2014 Medium

   Showed that natural MTARC2 coding variants reduce catalytic efficiency without abolishing cofactor binding, defining functionally consequential polymorphisms.

   Evidence Recombinant G244S and C245W variants, ICP-MS Moco saturation, steady-state kinetics with benzamidoxime

   PMID:24423752

   Open questions at the time

   • No in vivo or clinical correlation of variants
   • Single substrate tested
9. 2014 Medium

   Demonstrated MTARC2 reduces the drug metabolite SMX-HA more efficiently than mARC1, linking the enzyme to xenobiotic detoxification in cells.

   Evidence siRNA knockdown in HEK-293, recombinant enzyme kinetics, and subcellular fractionation with outer membrane vesicles

   PMID:25170804

   Open questions at the time

   • Single lab
   • In vivo relevance not tested
10. 2015 Medium

    Connected MTARC2-specific reductive detoxification to cell survival by showing it protects against apoptosis from a mutagenic base analog.

    Evidence RNAi knockdown in HeLa with flow-cytometric apoptosis quantification and PARP cleavage western blot

    PMID:25713076

    Open questions at the time

    • Isoform distinction shown but mechanism of mARC2 specificity unexplained
    • Single cell line
11. 2015 Medium

    Linked MTARC2 activity to lipid composition and to bioactivation of a mitotoxic prodrug metabolite in adipocytes.

    Evidence siRNA knockdown in murine adipocytes with lipidomics and Seahorse mitochondrial respiration

    PMID:26378779

    Open questions at the time

    • Mechanism connecting N-reductase activity to lipid metabolism not resolved
    • Trends not all statistically significant
12. 2019 High

    Genetic knockout established MTARC2 as the primary N-reductive enzyme in mice and a regulator of whole-body energy homeostasis.

    Evidence MARC2 knockout mouse with in vivo/in vitro N-reductase assays and high-fat-diet metabolic phenotyping

    PMID:31554661

    Open questions at the time

    • Molecular link between N-reductase activity and metabolic phenotype not defined
    • Mouse-to-human extrapolation untested
13. 2020 Medium

    Placed MTARC2 in a tumor-suppressive pathway in hepatocellular carcinoma acting through Hippo signaling, RNF123, p27, and HNF4A.

    Evidence In vitro and xenograft overexpression/knockdown, p27 western blot, reporter and ChIP assays, promoter methylation analysis

    PMID:32811980

    Open questions at the time

    • Connection between enzymatic activity and tumor suppression unestablished
    • Single lab
14. 2022 Medium

    Quantified isoform-specific tissue distribution, showing MTARC2 dominance in kidney relative to mARC1.

    Evidence Targeted quantitative proteomics across human liver and kidney fractions in pediatric and adult cohorts

    PMID:34949674

    Open questions at the time

    • Functional consequence of differential distribution not tested
15. 2022 Low

    Associated MTARC2 with tumor antigen presentation and immune phenotype in HCC via lipid-metabolism signaling.

    Evidence MARC2 overexpression in HCC lines with flow cytometry, expression analysis of HLA-C/B2M/PPARA

    PMID:35173763

    Open questions at the time

    • Correlative with limited mechanistic validation of the PPARA-HLA linkage
    • No in vivo confirmation
16. 2023 Medium

    Extended MTARC2 substrate scope beyond N-O bonds by showing it reduces hydrogen peroxide, implicating it in oxidative-stress responses.

    Evidence In vitro recombinant enzyme assay and MTARC1 knockout HEK-293T H2O2 sensitivity assay

    PMID:37687214

    Open questions at the time

    • Cellular sensitivity tested for MTARC1 knockout, not MTARC2-specific
    • Physiological significance unclear
17. 2025 Medium

    Identified MTARC2 as a bat-enriched coronavirus restriction factor acting through interaction with viral Orf9b.

    Evidence AP-MS in human and bat cells with comparative PPI mapping and viral replication assays using single-residue Orf9b variants

    PMID:42134328

    Open questions at the time

    • Mechanism of restriction downstream of Orf9b binding not defined
    • Whether enzymatic activity is involved unknown

• How MTARC2's outer-mitochondrial N-reductase chemistry mechanistically drives its diverse physiological roles — energy homeostasis, tumor suppression, and viral restriction — remains unresolved.
• No holoenzyme structure of the three-protein complex
• No causal link between catalytic activity and metabolic/oncologic phenotypes
• Mechanism of Orf9b-mediated coronavirus restriction undefined